featured
Pembrolizumab Plus Paclitaxel or Capecitabine as First- or Second-Line Therapy for Metastatic TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
NPJ Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer
NPJ Breast Cancer 2023 Jun 21;9(1)53, DB Page, J Pucilowska, B Chun, I Kim, K Sanchez, N Moxon, S Mellinger, Y Wu, Y Koguchi, V Conrad, WL Redmond, M Martel, Z Sun, MB Campbell, A Conlin, A Acheson, R Basho, P McAndrew, M El-Masry, D Park, L Bennetts, RS Seitz, TJ Nielsen, K McGregor, V Rajamanickam, B Bernard, WJ Urba, HL McArthurFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.